Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Buy at StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report released on Friday.

TEVA has been the topic of several other research reports. Piper Sandler upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Monday, February 5th. Barclays lifted their price target on Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a report on Friday, March 8th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and boosted their price target for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $14.11.

Teva Pharmaceutical Industries Stock Up 1.6 %

Shares of TEVA stock traded up $0.26 on Friday, hitting $16.26. The stock had a trading volume of 13,819,690 shares, compared to its average volume of 9,278,602. Teva Pharmaceutical Industries has a 52-week low of $7.09 and a 52-week high of $16.57. The firm has a market capitalization of $18.23 billion, a price-to-earnings ratio of -34.60, a P/E/G ratio of 1.68 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The stock's 50 day moving average is $13.81 and its 200-day moving average is $11.81.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the sale, the vice president now directly owns 1 shares in the company, valued at $13.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Eric Drape sold 173,261 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares of the company's stock, valued at approximately $13.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares in the company, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Insiders sold 358,972 shares of company stock worth $4,739,820 in the last 90 days. 0.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its stake in Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock valued at $46,000 after purchasing an additional 2,180 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company's stock worth $51,000 after acquiring an additional 2,394 shares in the last quarter. Psagot Value Holdings Ltd. Israel acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $57,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $82,000. Finally, Desjardins Global Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company's stock valued at $85,000 after purchasing an additional 1,070 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.